Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination product is an ophthalmic solution designed for the management of moderate to severe dry eye syndrome. It combines the hydrating and lubricating properties of **sodium hyaluronate**, a naturally occurring polysaccharide that retains water and stabilizes the tear film, with **trehalose**, a disaccharide that provides bioprotection to the corneal epithelium against desiccation and osmotic stress. The addition of **N-acetyl-glucosamine (NAG)**, a precursor to glycosaminoglycans, is intended to support the repair of the ocular surface and enhance the synthesis of natural hyaluronic acid. Together, these components work synergistically to restore tear film osmolarity, protect the ocular surface from environmental damage, and promote the healing of corneal micro-lesions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium hyaluronate + trehalose + N-acetyl-glucosamine.